Groupama Asset Managment Has $33.96 Million Stake in AbbVie Inc. $ABBV

Groupama Asset Managment lowered its stake in AbbVie Inc. (NYSE:ABBV) by 2.3% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 156,150 shares of the company’s stock after selling 3,644 shares during the quarter. Groupama Asset Managment’s holdings in AbbVie were worth $33,961,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in ABBV. Brighton Jones LLC boosted its position in AbbVie by 17.4% in the fourth quarter. Brighton Jones LLC now owns 22,912 shares of the company’s stock valued at $4,072,000 after buying an additional 3,401 shares in the last quarter. Revolve Wealth Partners LLC increased its holdings in shares of AbbVie by 72.7% during the fourth quarter. Revolve Wealth Partners LLC now owns 7,279 shares of the company’s stock worth $1,294,000 after buying an additional 3,064 shares in the last quarter. Schnieders Capital Management LLC. lifted its stake in shares of AbbVie by 5.0% in the 2nd quarter. Schnieders Capital Management LLC. now owns 16,466 shares of the company’s stock valued at $3,056,000 after acquiring an additional 789 shares during the last quarter. Ieq Capital LLC lifted its stake in shares of AbbVie by 4.6% in the 2nd quarter. Ieq Capital LLC now owns 120,035 shares of the company’s stock valued at $22,281,000 after acquiring an additional 5,274 shares during the last quarter. Finally, Worldquant Millennium Advisors LLC boosted its holdings in shares of AbbVie by 117.3% during the 2nd quarter. Worldquant Millennium Advisors LLC now owns 1,135,034 shares of the company’s stock valued at $210,685,000 after acquiring an additional 612,702 shares in the last quarter. 70.23% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of brokerages recently weighed in on ABBV. Piper Sandler restated an “overweight” rating and set a $298.00 price objective on shares of AbbVie in a research report on Tuesday, June 23rd. BMO Capital Markets increased their target price on AbbVie from $258.00 to $300.00 and gave the company an “outperform” rating in a research report on Monday, July 13th. Morgan Stanley lifted their price target on AbbVie from $270.00 to $278.00 and gave the company an “overweight” rating in a research note on Thursday, April 30th. DZ Bank upgraded AbbVie from a “hold” rating to a “strong-buy” rating in a report on Thursday, April 30th. Finally, Wall Street Zen lowered shares of AbbVie from a “strong-buy” rating to a “buy” rating in a report on Sunday, July 5th. Two analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have given a Hold rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $269.29.

Trending Headlines about AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Solid second-quarter results: AbbVie reported adjusted EPS of $3.65, above the $3.60 consensus estimate, while revenue rose 10.2% year over year to $16.99 billion. Reuters article
• Positive Sentiment: Immunology and neuroscience remained growth drivers: Skyrizi revenue reached $5.505 billion and Rinvoq generated $2.525 billion, while neuroscience revenue increased 20.3% to $3.228 billion. Botox also showed signs of stabilization, supporting the company’s diversified growth profile. AbbVie earnings release
• Positive Sentiment: Pipeline and portfolio expansion: AbbVie is advancing a global Phase 2/3 combination study in acute myeloid leukemia and recently received European approval for Rinvoq in severe alopecia areata, adding potential long-term growth opportunities. AML trial article
• Neutral Sentiment: Near-term guidance was broadly in line: Third-quarter adjusted EPS guidance of $3.84–$3.88 brackets the $3.85 consensus estimate, but revenue guidance of approximately $17.2 billion is slightly below the $17.3 billion analyst forecast.
• Negative Sentiment: Full-year EPS outlook was reduced: AbbVie lowered 2026 adjusted EPS guidance to $13.87–$14.07 from $13.91–$14.11. The revised range includes an estimated $0.14-per-share dilution from the planned $10.9 billion acquisition of Apogee Therapeutics, pushing the midpoint below Wall Street expectations. Zacks guidance article
• Negative Sentiment: Acquisition and execution concerns weigh on sentiment: Investors are balancing Apogee’s potential to strengthen AbbVie’s immunology pipeline against its immediate earnings dilution, while oncology revenue fell 1.5% and aesthetics revenue was essentially flat during the quarter.

AbbVie Stock Down 2.4%

NYSE ABBV opened at $251.33 on Friday. The company has a market capitalization of $444.05 billion, a price-to-earnings ratio of 123.81, a PEG ratio of 0.85 and a beta of 0.30. AbbVie Inc. has a twelve month low of $187.62 and a twelve month high of $267.47. The stock has a fifty day simple moving average of $239.10 and a 200 day simple moving average of $224.05.

AbbVie (NYSE:ABBV) last announced its earnings results on Friday, July 31st. The company reported $3.65 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.61 by $0.04. The business had revenue of $16.99 billion during the quarter, compared to analyst estimates of $16.78 billion. AbbVie had a negative return on equity of 576.45% and a net margin of 5.79%.AbbVie’s revenue for the quarter was up 10.2% compared to the same quarter last year. During the same period last year, the company earned $2.97 EPS. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. Research analysts expect that AbbVie Inc. will post 14.14 earnings per share for the current fiscal year.

AbbVie Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, August 14th. Stockholders of record on Wednesday, July 15th will be given a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a dividend yield of 2.8%. The ex-dividend date is Wednesday, July 15th. AbbVie’s dividend payout ratio (DPR) is 340.89%.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.